What Are Remicade and Inflectra?
Remicade (infliximab) is the reference biologic drug used to treat autoimmune conditions like Crohn's disease, rheumatoid arthritis, psoriasis, and ulcerative colitis. Inflectra is the first biosimilar to Remicade, approved by the FDA in 2016 as a highly similar version with no clinically meaningful differences in safety, purity, or potency.[1]
How Do They Differ in Manufacturing and Approval?
Remicade, made by Janssen Biotech (Johnson & Johnson), uses a patented process developed in the 1990s. Inflectra, produced by Celltrion and Pfizer, is manufactured using a different cell line and process but undergoes rigorous FDA testing to confirm similarity. Biosimilars like Inflectra must prove interchangeability or similarity through clinical trials showing comparable efficacy and immunogenicity.[1][2]
Are They Used for the Same Conditions?
Yes. Both treat the same FDA-approved indications, including moderate-to-severe active rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis. Dosing is identical: infusions every 6-8 weeks after initial doses.[1]
Interchangeability and Switching
Inflectra is not automatically interchangeable with Remicade in the U.S. (as of 2023), meaning pharmacists cannot switch without prescriber approval in most states. Europe allows non-medical switching. Studies show no increased risk of loss of response or adverse events when switching from Remicade to Inflectra.[2]
Cost Savings with Inflectra
Inflectra costs 30-40% less than Remicade due to no brand marketing and different manufacturing. U.S. wholesale acquisition cost for Inflectra is around $1,200 per vial versus $1,800+ for Remicade, driving payer preference and higher adoption rates.[3]
Patent and Availability Timeline
Remicade's key composition-of-matter patent expired in 2015 in Europe (leading to Inflectra's launch) but faced U.S. litigation until 2016. Biosimilars like Inflectra gained U.S. market access then. Remicade exclusivity ended fully by 2023, paving the way for more competitors like Renflexis and Avsola.[1][4] Check DrugPatentWatch.com for exact expiry dates and litigation details: DrugPatentWatch - Infliximab Patents.
Patient-Reported Differences
Real-world data from switches show similar remission rates (80-90% at one year) and infusion reactions (under 5%). Some patients report minor tolerability differences due to excipients or individual responses, but no large-scale immunogenicity gaps.[2]
Sources
[1]: FDA - Inflectra Approval Summary
[2]: NOR-SWITCH Study on Biosimilar Switching
[3]: ICER Report on Biosimilar Pricing
[4]: DrugPatentWatch - Infliximab